Treatment for diseases such as Alzheimer’s disease and cancers remains a challenge, yet the market opportunity is huge. It is no wonder that Anavex Life Sciences Corp (OTCMKTS:AVXL) is actively focusing its resources to break in these promising treatment markets. The company recently unveiled clean trial data of two of its drug candidates currently in the early stages of clinical development. It is unclear how the two drugs would turn out to be through the remaining development stages, although early indications are encouraging and their revenue potential is also not in doubt.
At the recent International Conference on neurological disorders in France, representatives of Anavex Life Sciences Corp (OTCMKTS:AVXL) seized the opportunity to tell the world what they are developing and how the progress has been so far. The company represented data on ANAVEX 3-71 and ANAVEX 2-73, which are its two lead drug candidates that just concluded the initial trials and are advancing in their developments. In fact, one of the drugs is already in Phase 2a trial having left Phase 1 study with clean trial data.
The company has promised that it will continue updating shareholder and the public on the progress it is making in the development of ANAVEX 3-71 and ANAVEX 2-73.
ANAVEX 3-71
Preclinical assessment of ANAVEX 3-71 left researchers at Anavex Life Sciences Corp (OTCMKTS:AVXL) an excited team. The drug showed unique preclinical advantages in combating Alzheimer’s disease. The concoction showed innovative action mechanism that led to improvement of both neuroprotection and cognition in Alzheimer’s. The other positive actions noted with the drug are the abilities to reduce mitochondrial dysfunctions and inflammation. ANAVEX 3-71 is showing all the interesting promise of being a bridge cure for both disease modifications and cognitive impairments.
ANAVEX 2-73
Anavex Life Sciences Corp (OTCMKTS:AVXL) also presented amazing data on ANAVEX 2-73, which is its other Alzheimer’s disease focused treatment. The drug is currently in Phase 2a trial, but left Phase 1 study with impressive data, which makes the management of the company hopeful of a brighter future in its development. In addition to combating Alzheimer’s disease, ANAVEX 2-73 is also showing promising for other CNS indications.
AVXL’s CEO, Christopher U. Missling, said they will be able to unveile more data in the ongoing studies in the next quarter.
